- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04522869
Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Biliary Atresia (UCMSCBA)
Evaluation Safety and Efficacy of Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia: A Matched Control Prospective Study
Biliary atresia (BA) is the most frequent cause of chronic cholestasis in neonates, accounting for at least 50% of pediatric liver transplantation. BA incidence is estimated to range from 1:5000 to 1:19000 live births. All patients will die due to complications of liver cirrhosis if the operation is not performed. Recently, mesenchymal stem cell (MSC) transplantation has been found as a promising therapy for liver cirrhosis in adults. Bone marrow-derived stem cell transplantation was also performed successfully for children with BA. Compared to MSC isolation from bone marrow, isolating MSCs from umbilical cord (UC) tissue is a less invasive procedure.
Furthermore, UC-derived MSCs (UC-MSCs) have been demonstrated to be safe and effective for liver cirrhosis in adults and different pediatric diseases, including liver cirrhosis due to primary biliary cirrhosis. The investigators will compare the outcomes of 17 Kasai operated BA patients who receive UC-MSC transplantation to 17 BA patients who only undergo Kasai operation. Two transplantations of UC - MSCs will be performed via the hepatic artery: the first transplant will be performed at baseline, and the second one will be performed 6 months later with a dosage of 1 million MSCs per kg of body weight. The frequency and severity of the adverse events or serious adverse events associated with UC-MSC injection at 72 hours post-injection will be used to assess the safety. The efficacy of the therapy will be measured using Pediatric End-Stage Liver Disease (PELD) score, liver function, and liver biopsy. This study would open a novel cell therapy to improve outcomes of patients with BA.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Phuong Nguyen
- Phone Number: 1421 (+84) 243 975
- Email: v.phuongnh9@vinmec.com
Study Locations
-
-
-
Hanoi, Vietnam, 10000
- Not yet recruiting
- Vinmec Research Institute of Stem Cell and Gene Technology
-
Contact:
- Phuong Nguyen, MPH
-
-
Hanoi
-
Hà Nội, Hanoi, Vietnam, 100000
- Recruiting
- Vinmec International Hospital Times City
-
Contact:
- Anh Hai Nguyen, MD, PhD
- Phone Number: (+84)968863668
- Email: haianhnguyenbm@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children diagnosed with liver cirrhosis due to biliary atresia after Kasai's operation
- From 5 months to 2 years old
- Weight ≥ 6 kg
- Patients with manifestation of cirrhosis on liver biopsy during Kasai's operation.
- Parents or primary caregivers signed the informed consent form.
Exclusion Criteria:
- Under 6kg or over 2 years old
- Coagulation disorders
- Allergy to anesthetic agents
- Active infections
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Umbilical cord blood - derived mesenchymal stem cells
17 patients with BA underwent Kasai operation and then will received two doses of UC-MSCs at 1x106 cells/kg (body weight) administered via hepatic artery
|
Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia
|
No Intervention: Control group
17 patients with BA will be conducted Kasai operation only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change of PELD scores during study
Time Frame: baseline, 3 months, 6 months, 9 months, 12 months
|
The PELD score is calculated using the following formula: PELD Score = 0.480 * ln (Bilirubin in mg/dL) + 1.857 * ln (INR) - 0.687 * ln (Albumin in g/dL) + 0.436 if the patient is <1 year old + 0.667 if there growth failure |
baseline, 3 months, 6 months, 9 months, 12 months
|
The change of albumin (Liver function)
Time Frame: up to the 12-month period following treatment
|
Levels of albumin (g/dL)
|
up to the 12-month period following treatment
|
The change of total bilirubin (Liver function)
Time Frame: up to the 12-month period following treatment
|
Total bilirubin level (mg/dL)
|
up to the 12-month period following treatment
|
The change of prothrombin time
Time Frame: up to the 12-month period following treatment
|
Prothrombin time (second)
|
up to the 12-month period following treatment
|
The change of liver biopsy
Time Frame: up to the 12-month period following treatment
|
change of liver biopsy
|
up to the 12-month period following treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of Adverse Events (AE) and Serious Adverse Events (SAE)
Time Frame: baseline, 3 months, 6 months, 9 months, 12 months (time frame: up to the 12-month period following treatment)
|
Adverse Events (AE) and Serious Adverse Events (SAE) after MSC transplantation
|
baseline, 3 months, 6 months, 9 months, 12 months (time frame: up to the 12-month period following treatment)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Liem Nguyen, Vinmec Research Institute of Stem Cell and Gene Technology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISC.19.10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Biliary Cirrhosis
-
University Health Network, TorontoUnknown
-
CymaBay Therapeutics, Inc.TerminatedPrimary Biliary Cirrhosis (PBC)Germany, United States, Canada, United Kingdom, Poland
-
Xijing Hospital of Digestive DiseasesUnknownPrimary Biliary CirrhosisChina
-
University of AarhusAarhus University Hospital; Hvidovre University HospitalRecruiting
-
CymaBay Therapeutics, Inc.RecruitingPrimary Biliary CirrhosisUnited States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
-
Target PharmaSolutions, Inc.Active, not recruitingBiliary Cirrhosis, PrimaryUnited States
-
IpsenActive, not recruitingPrimary Biliary CirrhosisUnited States, France, Spain, Belgium, Germany, Switzerland, Brazil, United Kingdom, Argentina, Canada, Chile, Italy, South Africa, Turkey
-
Instituto Mexicano del Seguro SocialActive, not recruitingPrimary Biliary CirrhosisMexico
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
Zydus Therapeutics Inc.CompletedPrimary Biliary CirrhosisUnited States
Clinical Trials on Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation
-
PT. Prodia Stem Cell IndonesiaEnrolling by invitationRetinitis PigmentosaIndonesia
-
PT. Prodia Stem Cell IndonesiaCompletedRetinitis PigmentosaIndonesia
-
Cytopeutics Sdn. Bhd.Universiti Tunku Abdul RahmanActive, not recruitingAcute-graft-versus-host DiseaseMalaysia
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWest China Hospital; Shanghai East HospitalUnknownSpinal Cord InjuriesChina
-
Affiliated Hospital to Academy of Military Medical...Unknown
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWest China Hospital; Shanghai East HospitalUnknownSpinal Cord InjuryChina
-
Cancer Institute and Hospital, Chinese Academy...UnknownComplications of Organ Transplant Stem Cells Umbilical CordChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWest China Hospital; Shanghai East HospitalUnknownSpinal Cord InjuriesChina
-
Affiliated Hospital to Academy of Military Medical...UnknownAcute GVH DiseaseChina
-
Indonesia UniversityPT. Prodia Stem Cell IndonesiaNot yet recruitingST Elevation Myocardial InfarctionIndonesia